August 17, 2021
Oncolys BioPharma said on August 16 that the US FDA has completed its review of two new investigational drug applications (INDs) submitted by Transposon Therapeutics to initiate PII clinical studies for the nucleoside reverse transcriptase inhibitor OBP-601 (censavudine) in patients...read more